These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 18847557

  • 1. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT, Castellsagué X, Villa LL, Hildesheim A.
    Vaccine; 2008 Aug 19; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [Abstract] [Full Text] [Related]

  • 2. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT, Castellsagué X, Garland SM.
    Vaccine; 2012 Nov 20; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF.
    Adv Ther; 2009 Nov 20; 26(11):983-98. PubMed ID: 20024678
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group.
    Hum Vaccin; 2009 Oct 20; 5(10):705-19. PubMed ID: 19684472
    [Abstract] [Full Text] [Related]

  • 9. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
    Fruscalzo A, Londero AP, Bertozzi S, Lellè RJ.
    Minerva Med; 2016 Feb 15; 107(1):26-38. PubMed ID: 26473283
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of human papillomavirus vaccines: a systematic quantitative review.
    Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.
    Int J Gynecol Cancer; 2009 Oct 15; 19(7):1166-76. PubMed ID: 19823051
    [Abstract] [Full Text] [Related]

  • 14. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA, Perry CM.
    Drugs; 2006 Oct 15; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [Abstract] [Full Text] [Related]

  • 15. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A, Panwar K, Haque M, Cocuzza CE, Andrews N, Southern J, Turner P, Miller E, Beddows S.
    Vaccine; 2019 Apr 24; 37(18):2455-2462. PubMed ID: 30926298
    [Abstract] [Full Text] [Related]

  • 16. [HPV vaccination: principles, results and future perspectives].
    Rouzier R, Uzan C, Collinet P.
    J Gynecol Obstet Biol Reprod (Paris); 2007 Feb 24; 36(1):13-8. PubMed ID: 17293248
    [Abstract] [Full Text] [Related]

  • 17. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
    Yadav R, Zhai L, Tumban E.
    Viruses; 2019 Dec 23; 12(1):. PubMed ID: 31877975
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.